Skip to main content

AKRO

Stock
Health Care
Biotechnology

Performance overview

AKRO Price
Price Chart

Forward-looking statistics

Beta
1.73
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Company info

SectorHealth Care
IndustryBiotechnology
Employees48
Market cap$1.6B

Fundamentals

Enterprise value$3.6B
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity3.34

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.75
Dividend per share
Revenue per share
Avg trading volume (30 day)$102M
Avg trading volume (10 day)$104M
Put-call ratio

Macro factor sensitivity

Growth+9.6
Credit+17.5
Liquidity-9.7
Inflation+6.6
Commodities+2.4
Interest Rates-2.2

Valuation

Dividend yield0.00%
PEG Ratio-12.18
Price to sales
P/E Ratio-12.18
Enterprise Value to Revenue
Price to book3.81

Upcoming events

Next earnings dayMay 12, 2025
Next dividend day
Ex. dividend day

News

AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study

Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead product candidate, EFX.

Zacks Investment Research (January 29, 2025)
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why

On Monday, Akero Therapeutics, Inc. AKRO released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, due to metabolic dysfunction-associated steatohepatitis (MASH).

Benzinga (January 27, 2025)
Cramer's Stop Trading: Akero Therapeutics

CNBC's Jim Cramer explains why he is keeping an eye on shares of Akero Therapeutics.

CNBC Television (February 6, 2024)
Stocks trending October 10, 2023: Akero Therapeutics, Palantir, Hyatt Hotels

Stocks are higher in early trading on dovish commentary from Federal Reserve officials. Hyatt Hotels Corporation (H) shares jump as the company will be replacing National Instruments (NATI) on the S&P MidCap 400, starting on Thursday, October 12.

Yahoo Finance (October 10, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free